PBA
TYRA icon

Paradigm Biocapital Advisors’s Tyra Biosciences TYRA Stock Holding History

Paradigm Biocapital Advisors’s Portfolio TYRA Stock Details TYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$78.7M Buy
+2,054,991
New +$66.5M 1.61% 21

Other funds holding TYRA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
APMC
Alta Partners Management Company Jackson, Wyoming $151M AUM 296.21% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Paradigm Biocapital Advisors's TYRA Position: Q1 2026 in Review

Paradigm Biocapital Advisors opened a new position in Tyra Biosciences (TYRA) in Q1 2026: 2,054,991 shares worth $78.7M. The stake represents 1.61% of the portfolio and ranks #21 among its holdings.

164 funds tracked by Wall St. Rank hold TYRA as of Q1 2026.

  • Paradigm Biocapital Advisors held 2,054,991 shares of Tyra Biosciences worth $78.7M as of Q1 2026.
  • Tyra Biosciences was a new Paradigm Biocapital Advisors position in Q1 2026.
  • Tyra Biosciences made up 1.61% of Paradigm Biocapital Advisors's portfolio in Q1 2026, its #21 holding.
  • 164 funds tracked by Wall St. Rank held Tyra Biosciences as of Q1 2026.

Based on Paradigm Biocapital Advisors's 13F filing for Q1 2026, filed 15 May 2026.